Department of Experimental Diagnostic Imaging, Center for Advanced Biomedical Imaging Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
PLoS One. 2009 Nov 24;4(11):e7977. doi: 10.1371/journal.pone.0007977.
Early diagnosis of pancreatic carcinoma with highly sensitive diagnostic imaging methods could save lives of many thousands of patients, because early detection increases resectability and survival rates. Current non-invasive diagnostic imaging techniques have inadequate resolution and sensitivity for detection of small size ( approximately 2-3 mm) early pancreatic carcinoma lesions. Therefore, we have assessed the efficacy of positron emission tomography and computer tomography (PET/CT) imaging with beta-O-D-galactopyranosyl-(1,4')-2'-deoxy-2'-[(18)F]fluoroethyl-D-glucopyranose ([(18)F]FEDL) for detection of less than 3 mm orthotopic xenografts of L3.6pl pancreatic carcinomas in mice. [(18)F]FEDL is a novel radioligand of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein (HIP/PAP), which is overexpressed in peritumoral pancreatic acinar cells.
METHODOLOGY/PRINCIPAL FINDINGS: Dynamic PET/CT imaging demonstrated rapid accumulation of [(18)F]FEDL in peritumoral pancreatic tissue (4.04+/-2.06%ID/g), bi-exponential blood clearance with half-lives of 1.65+/-0.50 min and 14.14+/-3.60 min, and rapid elimination from other organs and tissues, predominantly by renal clearance. Using model-independent graphical analysis of dynamic PET data, the average distribution volume ratio (DVR) for [(18)F]FEDL in peritumoral pancreatic tissue was estimated as 3.57+/-0.60 and 0.94+/-0.72 in sham-operated control pancreas. Comparative analysis of quantitative autoradiographic images and densitometry of immunohistochemically stained and co-registered adjacent tissue sections demonstrated a strong linear correlation between the magnitude of [(18)F]FEDL binding and HIP/PAP expression in corresponding regions (r = 0.88). The in situ analysis demonstrated that at least a 2-4 fold apparent lesion size amplification was achieved for submillimeter tumors and to nearly half a murine pancreas for tumors larger than 3 mm.
CONCLUSION/SIGNIFICANCE: We have demonstrated the feasibility of detection of early pancreatic tumors by non-invasive imaging with [(18)F]FEDL PET/CT of tumor biomarker HIP/PAP over-expressed in peritumoral pancreatic tissue. Non-invasive non-invasive detection of early pancreatic carcinomas with [(18)F]FEDL PET/CT imaging should aid the guidance of biopsies and additional imaging procedures, facilitate the resectability and improve the overall prognosis.
通过高灵敏度的诊断成像方法早期诊断胰腺癌可以挽救数千名患者的生命,因为早期发现可提高可切除性和生存率。目前的非侵入性诊断成像技术对于检测小尺寸(约 2-3 毫米)的早期胰腺癌病变的分辨率和灵敏度不足。因此,我们评估了β-O-D-半乳糖吡喃基-(1,4')-2'-脱氧-2'-[(18)F]氟乙基-D-吡喃葡萄糖([(18)F]FEDL)用于检测小于 3 毫米的原位异种移植 L3.6pl 胰腺癌细胞在小鼠中的疗效。[(18)F]FEDL 是肝癌-肠-胰腺/胰腺炎相关蛋白(HIP/PAP)的新型放射性配体,在肿瘤周围胰腺腺泡细胞中过度表达。
方法/主要发现:动态 PET/CT 成像显示[(18)F]FEDL 在肿瘤周围胰腺组织中快速积聚(4.04+/-2.06%ID/g),双指数血液清除半衰期分别为 1.65+/-0.50 分钟和 14.14+/-3.60 分钟,并且迅速从其他器官和组织中清除,主要通过肾脏清除。使用动态 PET 数据的无模型图形分析,估计[(18)F]FEDL 在肿瘤周围胰腺组织中的平均分布容积比(DVR)为 3.57+/-0.60 和 0.94+/-0.72 在假手术对照胰腺中。定量免疫组织化学染色和共定位相邻组织切片的放射自显影图像比较分析表明,[(18)F]FEDL 结合的大小与相应区域中 HIP/PAP 表达之间存在很强的线性相关性(r=0.88)。原位分析表明,对于亚毫米肿瘤,至少可以实现 2-4 倍的表观病变大小放大,而对于大于 3 毫米的肿瘤,则可以放大近半只小鼠的胰腺。
结论/意义:我们已经证明了通过肿瘤生物标志物 HIP/PAP 在肿瘤周围胰腺组织中过度表达的[(18)F]FEDL PET/CT 进行非侵入性成像检测早期胰腺肿瘤的可行性。[(18)F]FEDL PET/CT 成像的早期胰腺癌的非侵入性检测应有助于指导活检和其他成像程序,提高可切除性并改善整体预后。